C&EN White Paper
Formulation innovation: Partnerships usher in next wave of solid dosage forms
Brought to you by Aenova

Active pharmaceutical ingredients, or APIs, are what make a drug a drug - they produce the desired effect. The process of formulation converts APIs into drug products that patients can use. Most marketed pharmaceutical drugs are manufactured in solid forms such as tablets, capsules, and powders. Now the long-standing, well standardized practice of formulation is facing new challenges. Some advanced APIs are not compatible with standard approaches to formulation due to issues with stability, solubility, or other physicochemical characteristics. In this whitepaper, you will learn about innovative new approaches to solid dosage formulation and how partnering with a contract development and manufacturing organization, or CDMO, that specializes in these techniques will benefit your drug development pipeline.

Key Objectives:
  • Understand the importance of solid dosage formulation
  • Learn how novel approaches to solid dosage formulation can improve bioavailability
  • Learn how innovative delivery systems can expand the utility of solid dosage forms
  • Understand what to look for in a CDMO formulation partner

Brought to you by:
Please complete the form to download the white paper.
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy .

Copyright © 2024 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy